John N Allan

24PUBLICATIONS
135CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical virologyHaematological tumoursOncology and carcinogenesis not elsewhere classifiedMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Feb 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Jia Ruan, David A Bond, Bijal Shah

|Nov 25, 2025
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Jia Ruan, David A Bond, Bijal Shah

|Jul 17, 2025
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemia.

Jorge J Castillo, Alberto Guijosa, John N Allan

|May 12, 2025
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL.

John N Allan, Tao Ran, Zhijie Ding

|Jan 09, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.

Max S Topp, Matthew Matasar, John N Allan

|Apr 10, 2024
An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.

Adam S Kittai, John N Allan, Dan James

Pageof 4

Frequent Collaborators

8 joint publications

Paul M Barr

5 joint publications

Jeffrey Pu

5 joint publications

Toby A Eyre

4 joint publications

Maryam Yazdy